StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Cara Therapeutics Price Performance
CARA stock opened at $4.75 on Wednesday. Cara Therapeutics has a 1 year low of $2.71 and a 1 year high of $13.80. The company has a market cap of $21.70 million, a P/E ratio of -2.71 and a beta of 0.51. The firm has a 50-day moving average of $4.07 and a 200 day moving average of $3.84.
Hedge Funds Weigh In On Cara Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. Disciplined Growth Investors Inc. MN grew its holdings in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the period. FMR LLC grew its holdings in Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Cara Therapeutics in the third quarter worth about $29,000. 44.66% of the stock is owned by institutional investors.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Recommended Stories
- Five stocks we like better than Cara Therapeutics
- The How and Why of Investing in Gold Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- The Most Important Warren Buffett Stock for Investors: His Own
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
